Tirzepatide inyowani mbiri mbiri GIP/GLP-1 receptor agonist yakaratidza chivimbiso chikuru mukurapa kwezvirwere zvemetabolism. Nekutevedzera zviito zvemahomoni maviri echisikigo incretin, inovandudza insulin secretion, inodzvanya mazinga eglucagon, uye inoderedza kudya kwekudya-zvinobatsira kudzora shuga yeropa uye kukurudzira kurasikirwa.
Panyaya yezviratidzo zvinotenderwa, tirzepatide parizvino inotenderwa kutonga kweglucose yeropa muvarwere vane Type 2 chirwere cheshuga uye kwenguva refu uremu manejimendi kune vanhu vane kufutisa kana kuwandisa. Kubudirira kwaro kwekiriniki kunotsigirwa zvakasimba nezvidzidzo zvakawanda: iyo SURPASS yekuedza yakatevedzana yakaratidza kuti tirzepatide inoderedza zvakanyanya HbA1c mazinga pamhando dzakasiyana siyana uye inodarika marapirwo aripo akadai semaglutide. Mukutonga uremu, iyo SURMOUNT miedzo yakaunza zvinokatyamadza mhedzisiro - vamwe varwere vakawana kuderedzwa kwehuremu hwe20% mukati megore, vachiisa tirzepatide seimwe yeanonyanya kushanda ekurwisa kufutisa pamusika.
Kupfuura chirwere cheshuga uye kufutisa, iyo inogona kushandiswa yetirzepatide iri kuwedzera. Miedzo yekiriniki inoenderera mberi iri kuongorora kushandiswa kwayo mukurapa mamiriro akaita seasiri doro steatohepatitis (NASH), chirwere cheitsvo chisingaperi, uye kutadza kwemoyo. Zvinonyanya kukosha, muchikamu che3 SUMMIT kuyedza, tirzepatide yakaratidza kudzikiswa kwakanyanya kwezviitiko zvine chekuita nemoyo kutadza pakati pevarwere vane moyo kutadza neyakachengetwa ejection chikamu (HFpEF) uye kufutisa, ichipa tariro nyowani yeakawanda ekurapa maapplication.
Nguva yekutumira: Jul-24-2025